Author: Jane Edwards|| Date Published: January 21, 2025
The National Institutes of Health has awarded the Alliance for Advancing Biomedical Research a potential 25-year, $89 billion recompete contract to manage and operate a federally funded research and development center, or FFRDC, of the National Cancer Institute.
NIH published a notice on SAM.gov on Friday announcing the award of the follow-on FFRDC contract to the Oakland, California-based nonprofit corporation.
What Is FNLCR?
The indefinite-delivery/indefinite-quantity contract covers the management and operation of NCI’s Frederick National Laboratory for Cancer Research, or FNLCR.
FNLCR is an FFRDC that provides biomedical research and development resources to advance the development of new technologies and transition basic science discoveries into novel agents to prevent, diagnose and treat cancer, HIV/AIDS and other diseases.
Researchers at NCI and across the country rely on the center for biomarker identification and validation, translational genomics, oncology-focused computational science and next-generation preclinical assay development, among others.
Contract Terms
The single-award IDIQ contract has a 10-year base term and three five-year option periods. It has a minimum guarantee of $5 million.
Cost, cost-plus-fixed-fee, cost-plus-award-fee and firm-fixed-price task orders are anticipated to be awarded under the parent contract.
NIH issued a solicitation for the recompete contract in June 2022.
Textron Aviation Defense has been awarded a five-year, $150 million contract to provide sustaining engineering and program management, or SEPM, services…
Merlin, an aerospace and defense technology company, has appointed former PsiQuantum executive Mark Brunner as chief revenue officer. What Will Mark Brunner Oversee?…
Fortreum has acquired Kovr.AI, an AI-native cybersecurity compliance platform, to combine automated compliance capabilities with independent assessment services for federal…
